Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVO NASDAQ:PLTR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$56.71+0.1%$55.80$45.05▼$119.07$253.37B0.6812.10 million shs7.30 million shsPLTRPalantir Technologies$178.70-0.6%$171.78$40.36▼$190.00$423.94B2.685.69 million shs31.27 million shsUTHRUnited Therapeutics$433.99+0.1%$377.79$266.98▼$459.48$19.58B0.66593,591 shs345,431 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S-1.45%-4.12%+3.15%-15.52%-52.68%PLTRPalantir Technologies+1.43%-1.33%+4.85%+19.10%+313.96%UTHRUnited Therapeutics-1.47%-5.08%+7.06%+45.43%+21.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$56.71+0.1%$55.80$45.05▼$119.07$253.37B0.6812.10 million shs7.30 million shsPLTRPalantir Technologies$178.70-0.6%$171.78$40.36▼$190.00$423.94B2.685.69 million shs31.27 million shsUTHRUnited Therapeutics$433.99+0.1%$377.79$266.98▼$459.48$19.58B0.66593,591 shs345,431 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S-1.45%-4.12%+3.15%-15.52%-52.68%PLTRPalantir Technologies+1.43%-1.33%+4.85%+19.10%+313.96%UTHRUnited Therapeutics-1.47%-5.08%+7.06%+45.43%+21.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.50Moderate Buy$76.0034.02% UpsidePLTRPalantir Technologies 2.14Hold$141.28-20.94% DownsideUTHRUnited Therapeutics 2.67Moderate Buy$457.215.35% UpsideCurrent Analyst Ratings BreakdownLatest PLTR, NVO, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025NVONovo Nordisk A/SBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform$50.00 ➝ $55.0010/14/2025PLTRPalantir TechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$182.00 ➝ $201.0010/14/2025NVONovo Nordisk A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$328.00 ➝ $435.0010/8/2025PLTRPalantir TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025UTHRUnited TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/1/2025NVONovo Nordisk A/SHSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.0010/1/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/1/2025NVONovo Nordisk A/SHSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$70.009/29/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$560.00 ➝ $580.009/29/2025NVONovo Nordisk A/SMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight$59.00 ➝ $47.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$42.12B6.01$3.85 per share14.74$4.66 per share12.17PLTRPalantir Technologies$2.87B147.94$0.09 per share1,920.77$2.18 per share81.97UTHRUnited Therapeutics$2.88B6.80$28.00 per share15.50$144.34 per share3.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$14.64B$3.6415.5912.172.6035.60%78.64%24.51%11/5/2025 (Estimated)PLTRPalantir Technologies$462.19M$0.30595.69525.599.6122.18%10.75%8.71%11/3/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6216.9415.794.8040.36%18.73%16.49%10/29/2025 (Estimated)Latest PLTR, NVO, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025NVONovo Nordisk A/S$0.90N/AN/AN/A$11.98 billionN/A11/3/2025Q3 2025PLTRPalantir Technologies$0.17N/AN/AN/A$1.09 billionN/A10/29/2025Q3 2025UTHRUnited Therapeutics$6.75N/AN/AN/A$812.87 millionN/A8/6/2025Q2 2025 NVONovo Nordisk A/S$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion8/4/2025Q2 2025PLTRPalantir Technologies$0.14$0.16+$0.02$0.13$939.29 million$1.00 billion7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$0.821.45%N/A22.53%N/APLTRPalantir TechnologiesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ALatest PLTR, NVO, and UTHR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025NVONovo Nordisk A/Ssemi-annual$0.41192.4%8/18/20258/18/20258/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.520.780.56PLTRPalantir TechnologiesN/A6.326.32UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%PLTRPalantir Technologies45.65%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%PLTRPalantir Technologies12.93%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionablePLTRPalantir Technologies3,9362.37 billion2.07 billionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionablePLTR, NVO, and UTHR HeadlinesRecent News About These CompaniesUnited Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025October 15 at 7:41 AM | finance.yahoo.comUnited Therapeutics to Feature Clinical Data at the CHEST 2025 Annual MeetingOctober 13 at 10:00 AM | finance.yahoo.comCallan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHROctober 13 at 5:58 AM | marketbeat.comInspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHROctober 12 at 4:37 AM | marketbeat.comPrime Capital Investment Advisors LLC Reduces Stake in United Therapeutics Corporation $UTHROctober 12 at 3:33 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of StockOctober 11, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)October 11, 2025 | theglobeandmail.comUnited Therapeutics Corporation $UTHR Shares Bought by Galvin Gaustad & Stein LLCOctober 11, 2025 | marketbeat.comMorgan Stanley Maintains United Therapeutics (UTHR) Equal-Weight RecommendationOctober 11, 2025 | msn.comUnited Therapeutics price target raised to $435 from $328 at Morgan StanleyOctober 10, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Earns Hold (C+) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 9, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,803,440.00 in StockOctober 9, 2025 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) Sets New 52-Week High - Here's What HappenedOctober 8, 2025 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of StockOctober 7, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,798,760.00 in StockOctober 7, 2025 | insidertrades.comQRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHROctober 6, 2025 | marketbeat.comPolaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHROctober 4, 2025 | marketbeat.comHilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHROctober 4, 2025 | marketbeat.comHow Investors Are Reacting To United Therapeutics (UTHR) Positive Phase 3 Results for Tyvaso in IPFOctober 3, 2025 | finance.yahoo.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,739,520.00 in StockOctober 3, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIs BigBear.ai the Next Palantir? By Gabriel Osorio-Mazilli | October 3, 2025Palantir Stock Eyes New Highs, Boosted by Boeing PartnershipBy Chris Markoch | October 1, 20255 Stocks Congress Quietly Bought in Q3—Should You Follow?By Thomas Hughes | October 10, 2025Palantir Expands UK Defense Role, Stock Eyes New HighsBy Chris Markoch | September 23, 2025AI Meets Nuclear: Palantir’s Role in Energy ExpansionBy Chris Markoch | October 9, 2025PLTR, NVO, and UTHR Company DescriptionsNovo Nordisk A/S NYSE:NVO$56.71 +0.05 (+0.09%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Palantir Technologies NASDAQ:PLTR$178.70 -1.04 (-0.58%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates under the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.United Therapeutics NASDAQ:UTHR$433.98 +0.38 (+0.09%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
